LPL Financial’s NovoCure NVCR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $123K | Sell |
11,330
-5,050
| -31% | -$63.1K | ﹤0.01% | 5629 |
|
|
2025
Q4 | $212K | Buy |
16,380
+2,153
| +15% | +$27.6K | ﹤0.01% | 5406 |
|
|
2025
Q3 | $184K | Sell |
14,227
-1,360
| -9% | -$18.2K | ﹤0.01% | 5375 |
|
|
2025
Q2 | $277K | Buy |
15,587
+3,626
| +30% | +$63.2K | ﹤0.01% | 4831 |
|
|
2025
Q1 | $213K | Sell |
11,961
-15,900
| -57% | -$361K | ﹤0.01% | 4824 |
|
|
2024
Q4 | $830K | Buy |
+27,861
| New | +$590K | ﹤0.01% | 3654 |
|
|
2024
Q3 | – | Sell |
-14,651
| Closed | -$251K | – | 5258 |
|
|
2024
Q2 | $251K | Sell |
14,651
-3,117
| -18% | -$54.8K | ﹤0.01% | 4393 |
|
|
2024
Q1 | $278K | Sell |
17,768
-2,940
| -14% | -$43.2K | ﹤0.01% | 4260 |
|
|
2023
Q4 | $309K | Buy |
20,708
+5,144
| +33% | +$68.8K | ﹤0.01% | 4069 |
|
|
2023
Q3 | $251K | Sell |
15,564
-7,776
| -33% | -$224K | ﹤0.01% | 4072 |
|
|
2023
Q2 | $969K | Sell |
23,340
-726
| -3% | -$45.1K | ﹤0.01% | 2857 |
|
|
2023
Q1 | $1.45M | Sell |
24,066
-770
| -3% | -$61.5K | ﹤0.01% | 2438 |
|
|
2022
Q4 | $1.82M | Buy |
24,836
+2,670
| +12% | +$201K | ﹤0.01% | 2136 |
|
|
2022
Q3 | $1.68M | Buy |
22,166
+2,805
| +14% | +$219K | ﹤0.01% | 2109 |
|
|
2022
Q2 | $1.35M | Buy |
19,361
+652
| +3% | +$49.1K | ﹤0.01% | 2332 |
|
|
2022
Q1 | $1.55M | Sell |
18,709
-4,287
| -19% | -$316K | ﹤0.01% | 2242 |
|
|
2021
Q4 | $1.73M | Buy |
22,996
+521
| +2% | +$52.3K | ﹤0.01% | 2201 |
|
|
2021
Q3 | $2.61M | Buy |
22,475
+5,345
| +31% | +$808K | ﹤0.01% | 1846 |
|
|
2021
Q2 | $3.8M | Sell |
17,130
-303
| -2% | -$58.9K | ﹤0.01% | 1536 |
|
|
2021
Q1 | $2.3M | Sell |
17,433
-7,216
| -29% | -$1.14M | ﹤0.01% | 1744 |
|
|
2020
Q4 | $4.26M | Sell |
24,649
-910
| -4% | -$125K | 0.01% | 1205 |
|
|
2020
Q3 | $2.85M | Buy |
25,559
+1,510
| +6% | +$121K | ﹤0.01% | 1268 |
|
|
2020
Q2 | $1.43M | Buy |
24,049
+3,791
| +19% | +$249K | ﹤0.01% | 1572 |
|
|
2020
Q1 | $1.36M | Buy |
20,258
+4,619
| +30% | +$365K | ﹤0.01% | 1424 |
|
|
2019
Q4 | $1.32M | Buy |
15,639
+391
| +3% | +$31.6K | ﹤0.01% | 1651 |
|
|
2019
Q3 | $1.14M | Sell |
15,248
-8,716
| -36% | -$697K | ﹤0.01% | 1630 |
|
|
2019
Q2 | $1.51M | Buy |
23,964
+10,268
| +75% | +$520K | ﹤0.01% | 1428 |
|
|
2019
Q1 | $660K | Sell |
13,696
-87
| -0.6% | -$4.19K | ﹤0.01% | 1979 |
|
|
2018
Q4 | $461K | Buy |
+13,783
| New | +$504K | ﹤0.01% | 2103 |
|
Other funds holding NVCR
SCM
VPM
VCM
QCM
LPL Financial's NVCR Position: Q1 2026 in Review
LPL Financial reduced its NovoCure (NVCR) stake by 31% in Q1 2026, selling an estimated $63.1K and leaving 11,330 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #5629.
LPL Financial first reported a position in NVCR in Q4 2018 and has held it in 29 quarters since. The position peaked at $4.26M in Q4 2020. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.
- LPL Financial held 11,330 shares of NovoCure worth $123K as of Q1 2026.
- LPL Financial sold 5,050 NovoCure shares in Q1 2026, an estimated $63.1K.
- NovoCure made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #5629 holding.
- LPL Financial first reported a position in NovoCure in Q4 2018 and has held it in 29 quarters since.
- LPL Financial's NovoCure position peaked at $4.26M in Q4 2020.
- 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.
Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.